{"id":534309,"date":"2026-06-04T20:42:21","date_gmt":"2026-06-04T20:42:21","guid":{"rendered":"https:\/\/www.newjerseyheadlines.com\/news\/story\/534309\/anal-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-incyte-corp-biomimetix-inovio-pharma-merck-sharp-dohme-dustin-deming-advaxis.html"},"modified":"2026-06-04T20:42:21","modified_gmt":"2026-06-04T20:42:21","slug":"anal-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-incyte-corp-biomimetix-inovio-pharma-merck-sharp-dohme-dustin-deming-advaxis","status":"publish","type":"post","link":"https:\/\/www.ohionewsdesk.com\/news\/story\/534309\/anal-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-incyte-corp-biomimetix-inovio-pharma-merck-sharp-dohme-dustin-deming-advaxis.html","title":{"rendered":"Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780597548.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 &ndash; DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1780597548.jpg\" alt=\"Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 &ndash; DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">The Key Anal Cancer Companies in the market include &#8211; Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH &amp; Co. KG, and others.<\/div>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s<strong> &ldquo;Anal Cancer Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Anal Cancer, historical and forecasted epidemiology as well as the Anal Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">The latest healthcare forecast report provides an in-depth analysis of Anal Cancer, offering comprehensive insights into the Anal Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Anal Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Anal Cancer therapies. Additionally, we cover the landscape of Anal Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Anal Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Anal Cancer space.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free sample for the Anal Cancer Market Forecast, Size &amp; Share Analysis Report: <\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/anal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/anal-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key facts of the Anal Cancer Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">The Anal Cancer market size was valued at around <strong>USD 12 million in 2025<\/strong> and is anticipated to grow to nearly <strong>USD 120 million by 2036<\/strong>, registering a robust <strong>CAGR of 24%<\/strong> between 2026 and 2036.<\/p>\n<\/li>\n<li>\n<p><strong>In October 2025, Oncolytics Biotech<\/strong> announced updated clinical data for Pelareorep in combination with atezolizumab in previously treated metastatic anal cancer, demonstrating an objective response rate of ~30%, which was more than double historical response rates seen with currently available therapies.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, Invion Limited<\/strong> announced that the US FDA granted Orphan Drug Designation to INV043 for the treatment of anal cancer, providing incentives to support the development of this therapy for a rare disease.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Incyte<\/strong> announced that the FDA had approved ZYNYZ, making it the first and only approved first-line treatment for advanced anal cancer patients in the US. In addition, the FDA approved ZYNYZ as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.<\/p>\n<\/li>\n<li>\n<p>Chemoradiotherapy (CRT) remains the standard of care for localized anal cancer, with ongoing research focusing on targeted therapies, immunotherapies, and novel chemotherapeutic agents to improve treatment outcomes.<\/p>\n<\/li>\n<li>\n<p><strong>Nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA)<\/strong> are considered second-line immunotherapy options for patients who do not respond to initial treatments.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&rsquo;s estimates, in 2025, there were nearly 20,500 incident cases of anal cancer in the 7MM, out of which the US accounted for the highest incident cases in 2025.<\/p>\n<\/li>\n<li>\n<p>In EU4 and the UK, females accounted for more incident cases of anal cancer, i.e., nearly 70%, as compared to males with incident cases of nearly 30%, in 2025.<\/p>\n<\/li>\n<li>\n<p>In 2025, among EU4 and the UK, Germany accounted for the highest number of cases of anal cancer, whereas Spain accounted for the least number of cases.<\/p>\n<\/li>\n<li>\n<p>As per the analysis, in the United States in 2025, anal cancer was found to be more incident in patients aged 65 years and above (~60%), followed by patients aged 50-64 years (~37%), and it was lowest in patients below 50 years (~4%).<\/p>\n<\/li>\n<li>\n<p>In 2025, Japan accounted for approximately 1,200 incident cases of anal cancer accounted for approximately, which was significantly lower compared to the EU4 and the US.<\/p>\n<\/li>\n<li>\n<p>In Japan, HPV negative (~1, 100 cases) cases of anal cancer were found to be more incident than HPV positive (~100 cases) in 2025<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Cancer Companies:<\/strong> Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH &amp; Co. KG, and others.<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Cancer Therapies:<\/strong> Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others<\/p>\n<\/li>\n<li>\n<p>The Anal Cancer market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anal Cancer pipeline products will significantly revolutionize the Anal Cancer market dynamics.<\/p>\n<\/li>\n<li>\n<p>The total number of incident cases of anal cancer in the 7MM was around 20,000 in 2023, and this is expected to rise by 2036, growing at a CAGR of 2.4% during the study period (2022&ndash;2036).<\/p>\n<\/li>\n<li>\n<p>The United States had the highest number of incident cases of anal cancer among the 7MM countries, and this number is expected to grow at a CAGR of 3.6% during the study period from 2022 to 2036.<\/p>\n<\/li>\n<li>\n<p>In 2023, around 82% of patients in the United States who tested positive for HPV were diagnosed with anal cancer, with HPV identified as the main contributing factor.<\/p>\n<\/li>\n<li>\n<p>In 2023, EU4 and the UK together recorded nearly 9,000 incident cases of anal cancer, a number expected to rise by 2036. Among the EU4 countries, Germany had the highest number of incident cases.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Anal cancer is a rare type of cancer that develops in the tissues of the anus, the opening at the end of the rectum. It often begins in the squamous cells lining the anal canal. Risk factors include human papillomavirus (HPV) infection, smoking, weakened immune system, and a history of anal or genital warts. Symptoms may include bleeding, pain, itching, or a lump near the anus. Treatment options typically involve surgery, radiation therapy, and chemotherapy, depending on the stage and spread of the cancer. Early detection significantly improves outcomes.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To Know in detail about the Anal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Cancer Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">Anal Cancer Epidemiology Segmentation:<\/p>\n<p style=\"text-align: justify\">The Anal Cancer market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Total Incident Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>Gender-specific Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>Age-specific Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>Histology-specific Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>HPV Status-specific Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>Stage-specific Cases of Anal Cancer<\/p>\n<\/li>\n<li>\n<p>Line-wise Treated Cases of Anal Cancer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download the report to understand which factors are driving Anal Cancer epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Cancer Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anal Cancer market or expected to get launched during the study period. The analysis covers Anal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify\">The report also covers the Anal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Ficerafusp alfa:<\/strong> Bicara Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>BMX-001:<\/strong> BioMimetix<\/p>\n<\/li>\n<li>\n<p><strong>Retifanlimab:<\/strong> Incyte Corporation<\/p>\n<\/li>\n<li>\n<p><strong>BMX-001:<\/strong> BioMimetix<\/p>\n<\/li>\n<li>\n<p><strong>VGX-3100:<\/strong> Inovio Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>9vHPV Vaccine:<\/strong> Merck Sharp &amp; Dohme<\/p>\n<\/li>\n<li>\n<p><strong>Pembrolizumab:<\/strong> Dustin Deming<\/p>\n<\/li>\n<li>\n<p><strong>cetuximab:<\/strong> AIDS Malignancy Consortium<\/p>\n<\/li>\n<li>\n<p><strong>Axalimogene filolisbac:<\/strong> Advaxis, Inc.<\/p>\n<\/li>\n<li>\n<p><strong>P16_37-63:<\/strong> Oryx GmbH &amp; Co. KG<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about therapies set to grab major Anal Cancer market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Cancer Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Increasing incidence of HPV-associated anal cancer, particularly among high-risk populations, is driving demand for effective treatment options.<\/p>\n<\/li>\n<li>\n<p>Growing awareness and improved screening practices are facilitating earlier diagnosis and increasing the number of patients entering treatment pathways.<\/p>\n<\/li>\n<li>\n<p>Advancements in immunotherapy and targeted therapies are expanding treatment options for advanced and recurrent anal cancer.<\/p>\n<\/li>\n<li>\n<p>Rising investment in oncology research and clinical trials is accelerating the development of novel therapeutics for anal cancer.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Anal Cancer Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Relatively low disease prevalence compared to other cancers limits patient populations and may reduce commercial incentives for drug development.<\/p>\n<\/li>\n<li>\n<p>Limited availability of approved targeted therapies restricts treatment choices, particularly for advanced or metastatic disease.<\/p>\n<\/li>\n<li>\n<p>Challenges in early detection and diagnosis can lead to delayed treatment and poorer clinical outcomes.<\/p>\n<\/li>\n<li>\n<p>High treatment costs and reimbursement constraints may hinder access to novel therapies in certain regions.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Anal Cancer Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Cancer Companies:<\/strong> Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH &amp; Co. KG, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Anal Cancer Therapies:<\/strong> Retifanlimab, BMX-001, VGX-3100, 9vHPV Vaccine, Pembrolizumab, cetuximab, Axalimogene filolisbac, P16_37-63, and others<\/p>\n<\/li>\n<li>\n<p><strong>Anal Cancer Therapeutic Assessment:<\/strong> Anal Cancer current marketed and Anal Cancer emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Anal Cancer Market Dynamics:<\/strong> Anal Cancer market drivers and Anal Cancer market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Anal Cancer Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Anal Cancer Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To know more about Anal Cancer companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/anal-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Anal Cancer Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify\">1. Anal Cancer Market Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary for Anal Cancer<\/p>\n<p style=\"text-align: justify\">3. SWOT analysis of Anal Cancer<\/p>\n<p style=\"text-align: justify\">4. Anal Cancer Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify\">5. Anal Cancer Market Overview at a Glance<\/p>\n<p style=\"text-align: justify\">6. Anal Cancer Disease Background and Overview<\/p>\n<p style=\"text-align: justify\">7. Anal Cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify\">8. Country-Specific Patient Population of Anal Cancer<\/p>\n<p style=\"text-align: justify\">9. Anal Cancer Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify\">10. Anal Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify\">11. Anal Cancer Emerging Therapies<\/p>\n<p style=\"text-align: justify\">12. Anal Cancer Market Outlook<\/p>\n<p style=\"text-align: justify\">13. Country-Wise Anal Cancer Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify\">14. Anal Cancer Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify\">15. Anal Cancer Market Drivers<\/p>\n<p style=\"text-align: justify\">16. Anal Cancer Market Barriers<\/p>\n<p style=\"text-align: justify\">17. Anal Cancer Appendix<\/p>\n<p style=\"text-align: justify\">18. Anal Cancer Report Methodology<\/p>\n<p style=\"text-align: justify\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify\">20. Disclaimer<\/p>\n<p style=\"text-align: justify\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=anal-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-incyte-corp-biomimetix-inovio-pharma-merck-sharp-dohme-dustin-deming-advaxis\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=anal-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-incyte-corp-biomimetix-inovio-pharma-merck-sharp-dohme-dustin-deming-advaxis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Anal Cancer Companies in the market include &#8211; Incyte Corporation, BioMimetix, Inovio Pharmaceuticals, Merck Sharp &amp; Dohme, Dustin Deming, Advaxis, Inc., Oryx GmbH &amp; Co. KG, and others.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/534309"}],"collection":[{"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/comments?post=534309"}],"version-history":[{"count":0,"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/posts\/534309\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/media?parent=534309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/categories?post=534309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ohionewsdesk.com\/news\/wp-json\/wp\/v2\/tags?post=534309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}